KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Astrazeneca (AZN) Invested Capital (2016 - 2025)

Astrazeneca has reported Invested Capital over the past 11 years, most recently at $78.3 billion for Q4 2025.

  • Quarterly results put Invested Capital at $78.3 billion for Q4 2025, up 10.08% from a year ago — trailing twelve months through Dec 2025 was $78.3 billion (up 10.08% YoY), and the annual figure for FY2025 was $78.3 billion, up 10.08%.
  • Invested Capital for Q4 2025 was $78.3 billion at Astrazeneca, up from $71.2 billion in the prior quarter.
  • Over the last five years, Invested Capital for AZN hit a ceiling of $78.3 billion in Q4 2025 and a floor of $66.3 billion in Q4 2022.
  • Median Invested Capital over the past 5 years was $70.1 billion (2021), compared with a mean of $70.7 billion.
  • Biggest five-year swings in Invested Capital: soared 94.54% in 2021 and later dropped 5.39% in 2022.
  • Astrazeneca's Invested Capital stood at $70.1 billion in 2021, then decreased by 5.39% to $66.3 billion in 2022, then rose by 2.26% to $67.8 billion in 2023, then grew by 4.98% to $71.2 billion in 2024, then rose by 10.08% to $78.3 billion in 2025.
  • The last three reported values for Invested Capital were $78.3 billion (Q4 2025), $71.2 billion (Q4 2024), and $67.8 billion (Q4 2023) per Business Quant data.